APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anthracycline Anticancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Anthracycline Anticancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025191 pages

Choose your research edition.

Industry ResearchAnthracycline Anticancer Drugs Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Anthracycline Anticancer Drugs Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Anthracycline Anticancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anthracycline Anticancer Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Anthracycline Anticancer Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Anthracycline Anticancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Anthracycline Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anthracycline Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anthracycline Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Anthracycline Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anthracycline Anticancer Drugs include Ebewe Pharma, Sicor Societa, Beijing Union Pharmaceutical, Hisun Pharmaceutical, Hanhui Pharmaceuticals, Pfizer, Jinyuan Pharmaceutical, Lingnan Pharmaceutical and Pude Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anthracycline Anticancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anthracycline Anticancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anthracycline Anticancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anthracycline Anticancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Anthracycline Anticancer Drugs Segment by Company

Ebewe Pharma

Sicor Societa

Beijing Union Pharmaceutical

Hisun Pharmaceutical

Hanhui Pharmaceuticals

Pfizer

Jinyuan Pharmaceutical

Lingnan Pharmaceutical

Pude Pharmaceutical

CSPC OUYI Pharmaceutical

Main Luck Pharmaceuticals

New Time Pharmaceutical

Anthracycline Anticancer Drugs Segment by Type

Aclarithromycin

Adriamycin

Pirarubicin

Epirubicin

Daunorubicin

Others

Anthracycline Anticancer Drugs Segment by Application

Stomach Cancer

Soft Tissue Sarcoma

Breast Cancer

Lymphoma

Acute Leukemia

Others

Anthracycline Anticancer Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anthracycline Anticancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anthracycline Anticancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anthracycline Anticancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anthracycline Anticancer Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anthracycline Anticancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Anthracycline Anticancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Anthracycline Anticancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Anthracycline Anticancer Drugs Industry Trends Table 2. Anthracycline Anticancer Drugs Industry Drivers Table 3. Anthracycline Anticancer Drugs Industry Opportunities and Challenges Table 4. Anthracycline Anticancer Drugs Industry Restraints Table 5. Global Anthracycline Anticancer Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Anthracycline Anticancer Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Anthracycline Anticancer Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Anthracycline Anticancer Drugs Sales Market Share by Manufacturers Table 9. Global Anthracycline Anticancer Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Anthracycline Anticancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Anthracycline Anticancer Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Anthracycline Anticancer Drugs Manufacturers, Product Type & Application Table 13. Global Anthracycline Anticancer Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Anthracycline Anticancer Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Aclarithromycin Table 17. Major Manufacturers of Adriamycin Table 18. Major Manufacturers of Pirarubicin Table 19. Major Manufacturers of Epirubicin Table 20. Major Manufacturers of Daunorubicin Table 21. Major Manufacturers of Others Table 22. Global Anthracycline Anticancer Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Anthracycline Anticancer Drugs Sales by Type (2021-2026) & (k units) Table 24. Global Anthracycline Anticancer Drugs Sales by Type (2027-2032) & (k units) Table 25. Global Anthracycline Anticancer Drugs Sales Market Share by Type (2021-2026) Table 26. Global Anthracycline Anticancer Drugs Sales Market Share by Type (2027-2032) Table 27. Global Anthracycline Anticancer Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 28. Global Anthracycline Anticancer Drugs Revenue by Type (2021-2026) & (k units) Table 29. Global Anthracycline Anticancer Drugs Revenue by Type (2027-2032) & (k units) Table 30. Global Anthracycline Anticancer Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Anthracycline Anticancer Drugs Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Stomach Cancer Table 33. Major Manufacturers of Soft Tissue Sarcoma Table 34. Major Manufacturers of Breast Cancer Table 35. Major Manufacturers of Lymphoma Table 36. Major Manufacturers of Acute Leukemia Table 37. Major Manufacturers of Others Table 38. Global Anthracycline Anticancer Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Anthracycline Anticancer Drugs Sales by Application (2021-2026) & (k units) Table 40. Global Anthracycline Anticancer Drugs Sales by Application (2027-2032) & (k units) Table 41. Global Anthracycline Anticancer Drugs Sales Market Share by Application (2021-2026) Table 42. Global Anthracycline Anticancer Drugs Sales Market Share by Application (2027-2032) Table 43. Global Anthracycline Anticancer Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 44. Global Anthracycline Anticancer Drugs Revenue by Application (2021-2026) & (k units) Table 45. Global Anthracycline Anticancer Drugs Revenue by Application (2027-2032) & (k units) Table 46. Global Anthracycline Anticancer Drugs Revenue Market Share by Application (2021-2026) Table 47. Global Anthracycline Anticancer Drugs Revenue Market Share by Application (2027-2032) Table 48. Global Anthracycline Anticancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 49. Global Anthracycline Anticancer Drugs Sales by Region (2021-2026) & (k units) Table 50. Global Anthracycline Anticancer Drugs Sales Market Share by Region (2021-2026) Table 51. Global Anthracycline Anticancer Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 52. Global Anthracycline Anticancer Drugs Sales Forecasted Market Share by Region (2027-2032) Table 53. North America Anthracycline Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. North America Anthracycline Anticancer Drugs Sales by Country (2021-2026) & (k units) Table 55. North America Anthracycline Anticancer Drugs Sales by Country (2027-2032) & (k units) Table 56. Europe Anthracycline Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Europe Anthracycline Anticancer Drugs Sales by Country (2021-2026) & (k units) Table 58. Europe Anthracycline Anticancer Drugs Sales by Country (2027-2032) & (k units) Table 59. Asia Pacific Anthracycline Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 60. Asia Pacific Anthracycline Anticancer Drugs Sales by Country (2021-2026) & (k units) Table 61. Asia Pacific Anthracycline Anticancer Drugs Sales by Country (2027-2032) & (k units) Table 62. South America, Middle East and Africa Anthracycline Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 63. South America, Middle East and Africa Anthracycline Anticancer Drugs Sales by Country (2021-2026) & (k units) Table 64. South America, Middle East and Africa Anthracycline Anticancer Drugs Sales by Country (2027-2032) & (k units) Table 65. Global Anthracycline Anticancer Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 66. Global Anthracycline Anticancer Drugs Revenue by Region (2021-2026) & (US$ Million) Table 67. Global Anthracycline Anticancer Drugs Revenue by Region (2027-2032) & (US$ Million) Table 68. Global Anthracycline Anticancer Drugs Revenue Market Share by Region (2021-2026) Table 69. Global Anthracycline Anticancer Drugs Revenue Market Share by Region (2027-2032) Table 70. Ebewe Pharma Company Information Table 71. Ebewe Pharma Business Overview Table 72. Ebewe Pharma Anthracycline Anticancer Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Ebewe Pharma Anthracycline Anticancer Drugs Product Portfolio Table 74. Ebewe Pharma Recent Development Table 75. Sicor Societa Company Information Table 76. Sicor Societa Business Overview Table 77. Sicor Societa Anthracycline Anticancer Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sicor Societa Anthracycline Anticancer Drugs Product Portfolio Table 79. Sicor Societa Recent Development Table 80. Beijing Union Pharmaceutical Company Information Table 81. Beijing Union Pharmaceutical Business Overview Table 82. Beijing Union Pharmaceutical Anthracycline Anticancer Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Beijing Union Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio Table 84. Beijing Union Pharmaceutical Recent Development Table 85. Hisun Pharmaceutical Company Information Table 86. Hisun Pharmaceutical Business Overview Table 87. Hisun Pharmaceutical Anthracycline Anticancer Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Hisun Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio Table 89. Hisun Pharmaceutical Recent Development Table 90. Hanhui Pharmaceuticals Company Information Table 91. Hanhui Pharmaceuticals Business Overview Table 92. Hanhui Pharmaceuticals Anthracycline Anticancer Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Hanhui Pharmaceuticals Anthracycline Anticancer Drugs Product Portfolio Table 94. Hanhui Pharmaceuticals Recent Development Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer Anthracycline Anticancer Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Pfizer Anthracycline Anticancer Drugs Product Portfolio Table 99. Pfizer Recent Development Table 100. Jinyuan Pharmaceutical Company Information Table 101. Jinyuan Pharmaceutical Business Overview Table 102. Jinyuan Pharmaceutical Anthracycline Anticancer Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Jinyuan Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio Table 104. Jinyuan Pharmaceutical Recent Development Table 105. Lingnan Pharmaceutical Company Information Table 106. Lingnan Pharmaceutical Business Overview Table 107. Lingnan Pharmaceutical Anthracycline Anticancer Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Lingnan Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio Table 109. Lingnan Pharmaceutical Recent Development Table 110. Pude Pharmaceutical Company Information Table 111. Pude Pharmaceutical Business Overview Table 112. Pude Pharmaceutical Anthracycline Anticancer Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Pude Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio Table 114. Pude Pharmaceutical Recent Development Table 115. CSPC OUYI Pharmaceutical Company Information Table 116. CSPC OUYI Pharmaceutical Business Overview Table 117. CSPC OUYI Pharmaceutical Anthracycline Anticancer Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. CSPC OUYI Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio Table 119. CSPC OUYI Pharmaceutical Recent Development Table 120. Main Luck Pharmaceuticals Company Information Table 121. Main Luck Pharmaceuticals Business Overview Table 122. Main Luck Pharmaceuticals Anthracycline Anticancer Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Main Luck Pharmaceuticals Anthracycline Anticancer Drugs Product Portfolio Table 124. Main Luck Pharmaceuticals Recent Development Table 125. New Time Pharmaceutical Company Information Table 126. New Time Pharmaceutical Business Overview Table 127. New Time Pharmaceutical Anthracycline Anticancer Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. New Time Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio Table 129. New Time Pharmaceutical Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Anthracycline Anticancer Drugs Distributors List Table 133. Anthracycline Anticancer Drugs Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Anthracycline Anticancer Drugs Product Image Figure 2. Global Anthracycline Anticancer Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anthracycline Anticancer Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Anthracycline Anticancer Drugs Sales (2021-2032) & (k units) Figure 5. Global Anthracycline Anticancer Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Anthracycline Anticancer Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Aclarithromycin Image Figure 9. Adriamycin Image Figure 10. Pirarubicin Image Figure 11. Epirubicin Image Figure 12. Daunorubicin Image Figure 13. Others Image Figure 14. Global Anthracycline Anticancer Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Anthracycline Anticancer Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Anthracycline Anticancer Drugs Sales Market Share by Type (2021-2032) Figure 17. Global Anthracycline Anticancer Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 18. Global Anthracycline Anticancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Anthracycline Anticancer Drugs Revenue Market Share by Type (2021-2032) Figure 20. Stomach Cancer Image Figure 21. Soft Tissue Sarcoma Image Figure 22. Breast Cancer Image Figure 23. Lymphoma Image Figure 24. Acute Leukemia Image Figure 25. Others Image Figure 26. Global Anthracycline Anticancer Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Anthracycline Anticancer Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 28. Global Anthracycline Anticancer Drugs Sales Market Share by Application (2021-2032) Figure 29. Global Anthracycline Anticancer Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 30. Global Anthracycline Anticancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 31. Global Anthracycline Anticancer Drugs Revenue Market Share by Application (2021-2032) Figure 32. North America Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 33. North America Anthracycline Anticancer Drugs Sales Market Share by Country (2021-2032) Figure 34. U.S. Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. Canada Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. Mexico Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Europe Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Europe Anthracycline Anticancer Drugs Sales Market Share by Country (2021-2032) Figure 39. Germany Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 40. France Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. U.K. Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. Italy Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. Netherlands Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. Asia Pacific Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. Asia Pacific Anthracycline Anticancer Drugs Sales Market Share by Country (2021-2032) Figure 46. China Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. Japan Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Korea Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. Southeast Asia Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. India Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. Australia Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. South America, Middle East and Africa Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. South America, Middle East and Africa Anthracycline Anticancer Drugs Sales Market Share by Country (2021-2032) Figure 54. Brazil Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. South Africa Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. Saudi Arabia Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 57. Turkey Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 58. Argentina Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 59. UAE Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 60. Egypt Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 61. Chile Anthracycline Anticancer Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 62. Global Anthracycline Anticancer Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 63. Global Anthracycline Anticancer Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 64. North America Anthracycline Anticancer Drugs Revenue (2021-2032) & (US$ Million) Figure 65. North America Anthracycline Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Europe Anthracycline Anticancer Drugs Revenue (2021-2032) & (US$ Million) Figure 67. Europe Anthracycline Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Asia-Pacific Anthracycline Anticancer Drugs Revenue (2021-2032) & (US$ Million) Figure 69. Asia-Pacific Anthracycline Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. South America, Middle East and Africa Anthracycline Anticancer Drugs Revenue (2021-2032) & (US$ Million) Figure 71. South America, Middle East and Africa Anthracycline Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 72. Anthracycline Anticancer Drugs Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Anthracycline Anticancer Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Aclarithromycin
  • Adriamycin
  • Pirarubicin
  • Epirubicin
  • Daunorubicin
  • Others
Applications
  • Stomach Cancer
  • Soft Tissue Sarcoma
  • Breast Cancer
  • Lymphoma
  • Acute Leukemia
  • Others
Companies covered
  • Ebewe Pharma
  • Sicor Societa
  • Beijing Union Pharmaceutical
  • Hisun Pharmaceutical
  • Hanhui Pharmaceuticals
  • Pfizer
  • Jinyuan Pharmaceutical
  • Lingnan Pharmaceutical
  • Pude Pharmaceutical
  • CSPC OUYI Pharmaceutical
  • Main Luck Pharmaceuticals
  • New Time Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anthracycline Anticancer Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anthracycline Anticancer Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Anthracycline Anticancer Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Anthracycline Anticancer Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Anthracycline Anticancer Drugs Market Dynamics
  1. 2.1 Anthracycline Anticancer Drugs Industry Trends
  2. 2.2 Anthracycline Anticancer Drugs Industry Drivers
  3. 2.3 Anthracycline Anticancer Drugs Industry Opportunities and Challenges
  4. 2.4 Anthracycline Anticancer Drugs Industry Restraints
3 Anthracycline Anticancer Drugs Market by Manufacturers
  1. 3.1 Global Anthracycline Anticancer Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Anthracycline Anticancer Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Anthracycline Anticancer Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Anthracycline Anticancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anthracycline Anticancer Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Anthracycline Anticancer Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Anthracycline Anticancer Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anthracycline Anticancer Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anthracycline Anticancer Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anthracycline Anticancer Drugs Tier 1, Tier 2, and Tier 3
4 Anthracycline Anticancer Drugs Market by Type
  1. 4.1 Anthracycline Anticancer Drugs Type Introduction
  2. 4.1.1 Aclarithromycin
  3. 4.1.2 Adriamycin
  4. 4.1.3 Pirarubicin
  5. 4.1.4 Epirubicin
  6. 4.1.5 Daunorubicin
  7. 4.1.6 Others
  8. 4.2 Global Anthracycline Anticancer Drugs Sales by Type
  9. 4.2.1 Global Anthracycline Anticancer Drugs Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Anthracycline Anticancer Drugs Sales by Type (2021-2032)
  11. 4.2.3 Global Anthracycline Anticancer Drugs Sales Market Share by Type (2021-2032)
  12. 4.3 Global Anthracycline Anticancer Drugs Revenue by Type
  13. 4.3.1 Global Anthracycline Anticancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Anthracycline Anticancer Drugs Revenue by Type (2021-2032)
  15. 4.3.3 Global Anthracycline Anticancer Drugs Revenue Market Share by Type (2021-2032)
5 Anthracycline Anticancer Drugs Market by Application
  1. 5.1 Anthracycline Anticancer Drugs Application Introduction
  2. 5.1.1 Stomach Cancer
  3. 5.1.2 Soft Tissue Sarcoma
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Lymphoma
  6. 5.1.5 Acute Leukemia
  7. 5.1.6 Others
  8. 5.2 Global Anthracycline Anticancer Drugs Sales by Application
  9. 5.2.1 Global Anthracycline Anticancer Drugs Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Anthracycline Anticancer Drugs Sales by Application (2021-2032)
  11. 5.2.3 Global Anthracycline Anticancer Drugs Sales Market Share by Application (2021-2032)
  12. 5.3 Global Anthracycline Anticancer Drugs Revenue by Application
  13. 5.3.1 Global Anthracycline Anticancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Anthracycline Anticancer Drugs Revenue by Application (2021-2032)
  15. 5.3.3 Global Anthracycline Anticancer Drugs Revenue Market Share by Application (2021-2032)
6 Global Anthracycline Anticancer Drugs Sales by Region
  1. 6.1 Global Anthracycline Anticancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anthracycline Anticancer Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Anthracycline Anticancer Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Anthracycline Anticancer Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anthracycline Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Anthracycline Anticancer Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Anthracycline Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Anthracycline Anticancer Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Anthracycline Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Anthracycline Anticancer Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Anthracycline Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Anthracycline Anticancer Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Anthracycline Anticancer Drugs Revenue by Region
  1. 7.1 Global Anthracycline Anticancer Drugs Revenue by Region
  2. 7.1.1 Global Anthracycline Anticancer Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Anthracycline Anticancer Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Anthracycline Anticancer Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Anthracycline Anticancer Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Anthracycline Anticancer Drugs Revenue (2021-2032)
  8. 7.2.2 North America Anthracycline Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Anthracycline Anticancer Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Anthracycline Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Anthracycline Anticancer Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Anthracycline Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Anthracycline Anticancer Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Anthracycline Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Ebewe Pharma
  2. 8.1.1 Ebewe Pharma Company Information
  3. 8.1.2 Ebewe Pharma Business Overview
  4. 8.1.3 Ebewe Pharma Anthracycline Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Ebewe Pharma Anthracycline Anticancer Drugs Product Portfolio
  6. 8.1.5 Ebewe Pharma Recent Developments
  7. 8.2 Sicor Societa
  8. 8.2.1 Sicor Societa Company Information
  9. 8.2.2 Sicor Societa Business Overview
  10. 8.2.3 Sicor Societa Anthracycline Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sicor Societa Anthracycline Anticancer Drugs Product Portfolio
  12. 8.2.5 Sicor Societa Recent Developments
  13. 8.3 Beijing Union Pharmaceutical
  14. 8.3.1 Beijing Union Pharmaceutical Company Information
  15. 8.3.2 Beijing Union Pharmaceutical Business Overview
  16. 8.3.3 Beijing Union Pharmaceutical Anthracycline Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Beijing Union Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
  18. 8.3.5 Beijing Union Pharmaceutical Recent Developments
  19. 8.4 Hisun Pharmaceutical
  20. 8.4.1 Hisun Pharmaceutical Company Information
  21. 8.4.2 Hisun Pharmaceutical Business Overview
  22. 8.4.3 Hisun Pharmaceutical Anthracycline Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Hisun Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
  24. 8.4.5 Hisun Pharmaceutical Recent Developments
  25. 8.5 Hanhui Pharmaceuticals
  26. 8.5.1 Hanhui Pharmaceuticals Company Information
  27. 8.5.2 Hanhui Pharmaceuticals Business Overview
  28. 8.5.3 Hanhui Pharmaceuticals Anthracycline Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hanhui Pharmaceuticals Anthracycline Anticancer Drugs Product Portfolio
  30. 8.5.5 Hanhui Pharmaceuticals Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Anthracycline Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Anthracycline Anticancer Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Jinyuan Pharmaceutical
  38. 8.7.1 Jinyuan Pharmaceutical Company Information
  39. 8.7.2 Jinyuan Pharmaceutical Business Overview
  40. 8.7.3 Jinyuan Pharmaceutical Anthracycline Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jinyuan Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
  42. 8.7.5 Jinyuan Pharmaceutical Recent Developments
  43. 8.8 Lingnan Pharmaceutical
  44. 8.8.1 Lingnan Pharmaceutical Company Information
  45. 8.8.2 Lingnan Pharmaceutical Business Overview
  46. 8.8.3 Lingnan Pharmaceutical Anthracycline Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lingnan Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
  48. 8.8.5 Lingnan Pharmaceutical Recent Developments
  49. 8.9 Pude Pharmaceutical
  50. 8.9.1 Pude Pharmaceutical Company Information
  51. 8.9.2 Pude Pharmaceutical Business Overview
  52. 8.9.3 Pude Pharmaceutical Anthracycline Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pude Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
  54. 8.9.5 Pude Pharmaceutical Recent Developments
  55. 8.10 CSPC OUYI Pharmaceutical
  56. 8.10.1 CSPC OUYI Pharmaceutical Company Information
  57. 8.10.2 CSPC OUYI Pharmaceutical Business Overview
  58. 8.10.3 CSPC OUYI Pharmaceutical Anthracycline Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 CSPC OUYI Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
  60. 8.10.5 CSPC OUYI Pharmaceutical Recent Developments
  61. 8.11 Main Luck Pharmaceuticals
  62. 8.11.1 Main Luck Pharmaceuticals Company Information
  63. 8.11.2 Main Luck Pharmaceuticals Business Overview
  64. 8.11.3 Main Luck Pharmaceuticals Anthracycline Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Main Luck Pharmaceuticals Anthracycline Anticancer Drugs Product Portfolio
  66. 8.11.5 Main Luck Pharmaceuticals Recent Developments
  67. 8.12 New Time Pharmaceutical
  68. 8.12.1 New Time Pharmaceutical Company Information
  69. 8.12.2 New Time Pharmaceutical Business Overview
  70. 8.12.3 New Time Pharmaceutical Anthracycline Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 New Time Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
  72. 8.12.5 New Time Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anthracycline Anticancer Drugs Value Chain Analysis
  2. 9.1.1 Anthracycline Anticancer Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anthracycline Anticancer Drugs Production Mode & Process
  6. 9.2 Anthracycline Anticancer Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anthracycline Anticancer Drugs Distributors
  9. 9.2.3 Anthracycline Anticancer Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst